Monday, August 6, 2018

RIL gains 1% on partnership with SBI; buys additional stake in Genesis Colors

Share price of Reliance Industries added more than 1 percent in the early trade on Friday as company formed a partnership with SBI to offer digital banking and financial services to their customers.

Jio and SBI are entering into a digital partnership aimed to increase SBI��s digital customer base multi-fold, also the customers will benefit from Jio Prime, a consumer engagement and commerce platform from Reliance, company said in release.

Reliance Brands, a subsidiary of the company, has purchased an additional 2.36 percent equity stake in Genesis Colors (GCL) for about Rs 9.89 crore, taking its total stake in GCL to 11.65 percent.

No regulatory approvals were required for the said acquisition of shares.

The investment does not fall within related party transaction and none of RIL's promoter/ promoter group/ group companies have interest in GCL.

At 09:17 hrs Reliance Industries was quoting at Rs 1,181.20, up Rs 12.85, or 1.10 percent on the BSE.

Disclosure: Reliance Industries Ltd. is the sole beneficiary of Independent Media Trust which controls Network18 Media & Investments Ltd.

Posted by Rakesh Patil First Published on Aug 3, 2018 09:35 am

Friday, August 3, 2018

-$0.59 Earnings Per Share Expected for argenx SE – (ARGX) This Quarter

Wall Street brokerages predict that argenx SE – (NASDAQ:ARGX) will report earnings per share (EPS) of ($0.59) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for argenx’s earnings, with estimates ranging from ($0.72) to ($0.52). The company is scheduled to issue its next earnings results before the market opens on Thursday, August 2nd.

According to Zacks, analysts expect that argenx will report full year earnings of ($2.62) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.38). For the next year, analysts expect that the company will post earnings of ($3.61) per share, with EPS estimates ranging from ($4.16) to ($3.20). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow argenx.

Get argenx alerts:

A number of equities research analysts have issued reports on ARGX shares. Cowen reaffirmed a “buy” rating on shares of argenx in a research report on Wednesday, June 6th. Wedbush reaffirmed an “outperform” rating and set a $92.00 target price (down previously from $93.00) on shares of argenx in a research report on Thursday, May 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $130.00 target price on shares of argenx in a research report on Thursday, June 7th. JMP Securities upped their target price on argenx from $93.00 to $130.00 and gave the stock a “positive” rating in a research report on Monday, June 18th. Finally, SunTrust Banks started coverage on argenx in a research report on Sunday, April 8th. They set a “buy” rating and a $125.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. argenx presently has a consensus rating of “Buy” and a consensus target price of $122.83.

A number of institutional investors have recently made changes to their positions in ARGX. Aperio Group LLC bought a new stake in argenx during the first quarter worth approximately $268,000. US Bancorp DE bought a new stake in argenx during the first quarter worth approximately $598,000. BB Biotech AG bought a new stake in argenx during the first quarter worth approximately $31,920,000. Northern Trust Corp bought a new stake in shares of argenx in the first quarter valued at approximately $896,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of argenx in the first quarter valued at approximately $498,000. 53.14% of the stock is owned by hedge funds and other institutional investors.

argenx traded down $0.20, reaching $91.93, during trading hours on Thursday, MarketBeat.com reports. 72,300 shares of the company were exchanged, compared to its average volume of 145,418. The stock has a market capitalization of $2.92 billion, a P/E ratio of -65.66 and a beta of 2.44. argenx has a 12 month low of $19.81 and a 12 month high of $103.00.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: Closed-End Mutual Funds

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Thursday, August 2, 2018

Investors Buy Shares of Altria Group (MO) on Weakness

Investors bought shares of Altria Group Inc (NYSE:MO) on weakness during trading on Wednesday. $138.79 million flowed into the stock on the tick-up and $49.20 million flowed out of the stock on the tick-down, for a money net flow of $89.59 million into the stock. Of all companies tracked, Altria Group had the 6th highest net in-flow for the day. Altria Group traded down ($0.60) for the day and closed at $58.08

Several brokerages recently issued reports on MO. Zacks Investment Research lowered shares of Altria Group from a “hold” rating to a “sell” rating in a report on Monday, May 14th. ValuEngine lowered shares of Altria Group from a “hold” rating to a “sell” rating in a report on Monday, April 23rd. Consumer Edge assumed coverage on Altria Group in a research report on Monday, June 11th. They issued an “equal weight” rating and a $69.31 target price for the company. Jefferies Financial Group set a $70.00 target price on Altria Group and gave the company a “buy” rating in a research report on Friday, June 1st. Finally, Stifel Nicolaus dropped their target price on Altria Group from $78.00 to $65.00 and set a “buy” rating for the company in a research report on Friday, July 27th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Altria Group presently has a consensus rating of “Buy” and an average price target of $71.61.

Get Altria Group alerts:

The stock has a market capitalization of $110.19 billion, a P/E ratio of 17.22, a PEG ratio of 1.70 and a beta of 0.62. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.65 and a quick ratio of 0.31.

Altria Group (NYSE:MO) last announced its quarterly earnings data on Thursday, July 26th. The company reported $1.01 EPS for the quarter, topping the Zacks’ consensus estimate of $1.00 by $0.01. Altria Group had a return on equity of 48.88% and a net margin of 42.00%. The business had revenue of $4.88 billion during the quarter, compared to the consensus estimate of $5.02 billion. During the same period in the previous year, the company posted $0.85 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. research analysts anticipate that Altria Group Inc will post 3.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 10th. Stockholders of record on Friday, June 15th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 4.82%. The ex-dividend date of this dividend was Thursday, June 14th. Altria Group’s dividend payout ratio is presently 82.84%.

Altria Group declared that its Board of Directors has approved a share buyback program on Thursday, May 17th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Several institutional investors have recently made changes to their positions in MO. Covington Capital Management boosted its holdings in Altria Group by 1.3% in the fourth quarter. Covington Capital Management now owns 60,403 shares of the company’s stock valued at $4,313,000 after purchasing an additional 803 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in Altria Group by 2.7% in the fourth quarter. Sterling Capital Management LLC now owns 31,228 shares of the company’s stock valued at $2,230,000 after purchasing an additional 812 shares in the last quarter. Segall Bryant & Hamill LLC boosted its holdings in Altria Group by 4.4% in the fourth quarter. Segall Bryant & Hamill LLC now owns 19,347 shares of the company’s stock valued at $1,382,000 after purchasing an additional 820 shares in the last quarter. Lido Advisors LLC boosted its holdings in Altria Group by 15.1% in the fourth quarter. Lido Advisors LLC now owns 6,275 shares of the company’s stock valued at $448,000 after purchasing an additional 825 shares in the last quarter. Finally, Wayne Hummer Investments L.L.C. boosted its holdings in Altria Group by 4.6% in the fourth quarter. Wayne Hummer Investments L.L.C. now owns 18,798 shares of the company’s stock valued at $1,342,000 after purchasing an additional 830 shares in the last quarter. 63.05% of the stock is owned by institutional investors and hedge funds.

About Altria Group

Altria Group, Inc, through its subsidiaries, manufactures and sells cigarettes, smokeless products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands.

Recommended Story: What is a Leveraged Buyout (LBO)?